Pulmonary hypertension life expectancy and prognosis can vary broadly, but have improved in the era of modern treatment.

Pulmonary hypertension (PH) has a high mortality rate if untreated. Unfortunately, the disease is not consistently diagnosed or treated across the United States. To improve the diagnosis and care of ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.

Panelists discuss how pulmonary arterial hypertension diagnosis requires comprehensive evaluation including right heart catheterization to confirm hemodynamic criteria, with normal mean PA pressure ...

Johnson & Johnson’s plan to expand decade-old pulmonary hypertension med Opsumit has hit a snag. J&J’s Janssen has decided to stop a phase 3 trial for a 75-mg dose of macitentan in patients with ...

Investigators provide recent information on the classification, pathophysiology, diagnosis, and treatment of pulmonary arterial hypertension, focusing specifically on its impact on women. Pulmonary ...

Early diagnosis of pulmonary arterial hypertension improves five-year survival by 42%, compared with delayed diagnosis, a ...

Tectonic Therapeutic reported positive Phase 1b trial results for TX45, showing improved hemodynamics in PH-HFpEF patients without serious adverse events. Despite the positive results, the company ...

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that go from your heart to your lungs. It happens when these arteries become narrow or blocked, making it harder ...